Related Experiment Video
Updated: Jan 22, 2026

Generation of Fluorescent Protein Fusions in Candida Species
Published on: March 4, 2017
Multidrug transporters of Candida species in clinical azole resistance
Rajendra Prasad1, Remya Nair1, Atanu Banerjee1
1Amity Institute of Integrative Science and Health and Amity Institute of Biotechnology, Amity University Haryana, Gurgaon, Haryana, India.
Abstract:
Over-expression of the human P-glycoprotein (P-gp) in tumor cells is a classic example of an ABC protein serving as a hindrance to effective chemotherapy. The existence of proteins homologous to P-gp in organisms encompassing the entire living kingdom highlights extrusion of drugs as a general mechanism of multidrug resistance. Infections caused by opportunistic human fungal pathogens such as Candida species are very common and has intensified in recent years. The typical hosts, who possess suppressed immune systems due to conditions such as HIV and transplantation surgery etc., are prone to fungal infections. Prolonged chemotherapy induces fungal cells to eventually develop tolerance to most of the antifungals currently in clinical use. Amongst other prominent mechanisms of antifungal resistance such as manipulation of the drug target, rapid efflux achieved through overexpression of multidrug transporters has emerged as a major resistance mechanism for azoles. Herein, the azole-resistant clinical isolates of Candida species utilize a few select efflux pump proteins belonging to the ABC and MFS superfamilies, to deter the toxic accumulation of therapeutic azoles and thus, facilitating cell survival. In this article, we summarize and discuss the clinically relevant mechanisms of azole resistance in Candida albicans and non-albicans Candida (NAC) species, specifically highlighting the role of multidrug efflux proteins in the phenomenon.
Insights
Multidrug efflux pumps, like P-glycoprotein (P-gp), are key to antifungal resistance in Candida species. Overexpression of these transporters helps fungi survive azole treatments, posing challenges for immunocompromised patients.
Area of Science:
- Mycology
- Molecular Biology
- Pharmacology
Background:
- Multidrug resistance (MDR) is a significant challenge in treating opportunistic fungal infections, particularly in immunocompromised individuals.
- Overexpression of efflux pumps, such as P-glycoprotein (P-gp), is a common mechanism for MDR in both cancer chemotherapy and antifungal treatments.
- Candida species, including Candida albicans and non-albicans Candida (NAC) species, are leading causes of invasive fungal infections.
Purpose of the Study:
- To summarize and discuss clinically relevant mechanisms of azole resistance in Candida species.
- To highlight the critical role of multidrug efflux proteins in mediating antifungal resistance.
- To provide insights into the challenges posed by azole-resistant fungal infections.
Main Methods:
- Review of existing literature on azole resistance mechanisms in Candida species.
- Focus on the role of efflux pump proteins belonging to the ABC and MFS superfamilies.
- Analysis of clinical isolates exhibiting azole resistance.
Main Results:
- Azole resistance in Candida species is significantly mediated by the overexpression of multidrug efflux pumps.
- Efflux proteins from the ATP-binding cassette (ABC) and Major Facilitator Superfamily (MFS) are crucial for extruding azole drugs.
- This efflux mechanism allows fungal cells to survive therapeutic azole concentrations.
Conclusions:
- Multidrug efflux proteins are a primary mechanism of azole resistance in clinical isolates of Candida albicans and NAC species.
- Understanding these efflux mechanisms is vital for developing strategies to overcome antifungal drug tolerance.
- Targeting or circumventing these efflux pumps may improve the efficacy of azole-based therapies against Candida infections.
More Related Videos
Related Concept Videos
What is a Species?
Keystone Species
Formation of Species
Facilitated Transport
Primary Active Transport
Secondary Active Transport

